Proglumide sodium salt (CAS No 99247-33-3) is a compound commonly used in biomedical research particularly in the study of gastrointestinal and pain modulation pathways It originates from the class of non-peptide cholecystokinin (CCK) antagonists and primarily targets CCK receptors Its mechanism involves the inhibition of CCK-mediated processes which can influence gastric acid secretion and motility as well as pain perception and opioid receptor activity modulation The compound exhibits in vitro activity often observed in the nanomolar to low micromolar range It is frequently utilized in various experimental setups including cell models and animal studies to explore its effects on gastric functions pancreatic secretions and analgesic pathways Additionally proglumide sodium salt serves in drug screening protocols to evaluate potential therapeutic effects and interactions with opioid systems Experimental concentrations typically depend on the specific research design